Phosphorylcholine-coated cardiopulmonary bypass in paediatric cardiac surgery improves biocompatibility: reduced contact activation and endothelin-1 release
Frank Harig, Robert Anton Cesnjevar, Yvonne Lindemann, Lars Bumiller, Helmut Singer, M Weyand · Critical Care · 2001
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Critical Care · BioMed Central · article · 2001
Abstract
Modification of cardiopulmonary bypass (CPB) circuits by using a phospholipid coating is a promising option for improving biocompatibility of CPB and thus reducing CPB-associated organ dysfunction. Endothelin-1 is a potent vasoconstrictor peptide that is synthesized and secreted by vascular endothelial cells. Its biological functions are widespread, acting as a mitogen and stimulant of collagen synthesis. It has been reported to be positively inotropic, to increase after vascular injury, and to induce pulmonary vasoconstriction, cardiac hypertrophy and heart failure.
The aim of this study was to analyze the impact of a new phospholipid coating with respect to contact activation and endothelin-1 release in paediatric cardiac surgery patients.
Open the resolved locator · 10.1186/cc1007
Metadata licence: OpenAlex metadata (CC0)